Summary
The purpose of this study was to compare the efficacy and safety of idarubicin-loaded drug-eluting beads-transarterial chemoembolization (IDA-TACE) and epirubicin-loaded drug-eluting beads-TACE (EPI-TACE) in treating hepatocellular carcinoma (HCC). All patients with HCC treated with TACE in our hospital between June 2020 and January 2022 were screened. The included patients were divided into the IDA-TACE group and EPI-TACE group to compare overall survival (OS), time to progression (TTP), objective response rate (ORR), and adverse events. There were 55 patients each in the IDA-TACE and EPI-TACE groups. Compared with the EPI-TACE group, the median TTP in the IDA-TACE group was not significantly different (10.50 vs. 9.23 months; HR 0.68; 95% CI 0.40–1.16; P = 0.154), whereas the survival status in the IDA-TACE group tended to be better (neither achieved; HR 0.47; 95% CI 0.22–1.02; P = 0.055). Based on the Barcelona Clinic Liver Cancer staging system for subgroup analysis, considering stage C patients, the IDA-TACE group performed significantly better in terms of ORR (77.1% vs. 54.3%, P = 0.044), median TTP (10.93 vs. 5.20 months; HR 0.46; 95% CI 0.24–0.89; P = 0.021), and median OS (not achieved vs. 17.80 months; HR 0.41; 95% CI 0.18–0.93; P = 0.033). Considering stage B patients, there were no significant differences between the IDA-TACE and EPI-TACE groups in terms of ORR (80.0% vs. 80.0%, P = 1.000), median TTP (10.20 vs. 11.2 months; HR 1.41; 95% CI 0.54–3.65; P = 0.483), or median OS (neither achieved, HR 0.47; 95% CI 0.04–5.24; P = 0.543). Notably, leukopenia was more common in the IDA-TACE group (20.0%, P = 0.052), and fever was more common in the EPI-TACE group (49.1%, P = 0.010). IDA-TACE was more effective than EPI-TACE in treating advanced-stage HCC and comparable in treating intermediate-stage HCC.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author on reasonable request.
Abbreviations
- AFP:
-
Alpha-fetoprotein
- ECOG:
-
Eastern Cooperative Oncology Group
- OS:
-
Overall survival
- IDA-TACE:
-
Idarubicin-DEB-TACE group
- EPI-TACE:
-
Epirubicin-DEB-TACE group
References
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Chen J-G, Zhu J, Zhang Y-H et al (2021) Liver Cancer Survival: A Real World Observation of 45 Years with 32,556 Cases. JHC 8:1023–1034. https://doi.org/10.2147/JHC.S321346
Bruix J, Reig M, Sherman M (2016) Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology 150:835–853. https://doi.org/10.1053/j.gastro.2015.12.041
Mokdad AA, Hester CA, Singal AG, Yopp AC (2017) Management of hepatocellular in the United States. Chin Clin Oncol 6:21–21. https://doi.org/10.21037/cco.2017.04.04
Raoul J-L, Forner A, Bolondi L et al (2019) Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 72:28–36. https://doi.org/10.1016/j.ctrv.2018.11.002
Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 76:681–693. https://doi.org/10.1016/j.jhep.2021.11.018
Galle PR, Forner A, Llovet JM et al (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
Park J, Chen M, Colombo M et al (2015) Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35:2155–2166. https://doi.org/10.1111/liv.12818
Llovet JM, Hilgard P, de Oliveira AC et al (2008) Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med 13
Chung GE, Lee J-H, Kim HY et al (2011) Transarterial Chemoembolization Can Be Safely Performed in Patients with Hepatocellular Carcinoma Invading the Main Portal Vein and May Improve the Overall Survival. Radiology 258:627–634. https://doi.org/10.1148/radiol.10101058
Gorodetski B, Chapiro J, Schernthaner R et al (2017) Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. Eur Radiol 27:526–535. https://doi.org/10.1007/s00330-016-4445-9
Pinter M, Hucke F, Graziadei I et al (2012) Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology 263:590–599. https://doi.org/10.1148/radiol.12111550
Boulin M, Guiu S, Chauffert B et al (2011) Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anticancer Drugs 22:741–748. https://doi.org/10.1097/CAD.0b013e328346a0c5
Boulin M, Schmitt A, Delhom E et al (2016) Improved stability of lipiodol–drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. Eur Radiol 26:601–609. https://doi.org/10.1007/s00330-015-3855-4
Roth GS, Teyssier Y, Abousalihac M et al (2020) Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. WJG 26:324–334. https://doi.org/10.3748/wjg.v26.i3.324
Boulin M, Hillon P, Cercueil JP et al (2014) Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. Aliment Pharmacol Ther 39:1301–1313. https://doi.org/10.1111/apt.12746
Guiu B, Chevallier P, Assenat E et al (2019) Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. Radiology 291:801–808. https://doi.org/10.1148/radiol.2019182399
Fan W, Zhu B, Yue S et al (2022) Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis. Cancer Med cam4.4937. https://doi.org/10.1002/cam4.4937
Lencioni R, Llovet J (2010) Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 30:052–060. https://doi.org/10.1055/s-0030-1247132
Johnson PJ, Berhane S, Kagebayashi C et al (2015) Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. JCO 33:550–558. https://doi.org/10.1200/JCO.2014.57.9151
Berman E, Heller G, Santorsa J et al (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666–1674. https://doi.org/10.1182/blood.V77.8.1666.1666
Guiu B, Jouve J-L, Schmitt A et al (2018) Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. J Hepatol 68:1163–1171. https://doi.org/10.1016/j.jhep.2018.01.022
Guiu C, Piron, et al (2019) Transarterial Chemoembolization of Hepatocellular Carcinoma with Idarubicin-Loaded Tandem Drug-Eluting Embolics. Cancers 11:987. https://doi.org/10.3390/cancers11070987
Parikh ND, Waljee AK, Singal AG (2015) Downstaging hepatocellular carcinoma: A systematic review and pooled analysis: Down-Staging Hepatocellular Carcinoma. Liver Transpl 21:1142–1152. https://doi.org/10.1002/lt.24169
Sun H-C, Zhu X-D (2021) Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Front Oncol 11:772195. https://doi.org/10.3389/fonc.2021.772195
Peng Z, Fan W, Zhu B et al Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol 12
Friberg LE, Henningsson A, Maas H et al (2002) Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs. JCO 20:4713–4721. https://doi.org/10.1200/JCO.2002.02.140
Piska K, Koczurkiewicz P, Bucki A et al (2017) Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents. Invest New Drugs 35:375–385. https://doi.org/10.1007/s10637-017-0443-2
Acknowledgements
The patients participating in this study are sincerely acknowledged.
Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Author information
Authors and Affiliations
Contributions
Conceptualization: Mingsheng Huang, Mingan Li, Chenghao Zhao. Data curation: Zhanwang **ang, Haofan Wang. Formal analysis: Huzheng Yan, Haofan Wang. Investigation: Chenghao Zhao, Huzheng Yan, Zhanwang **ang. Methodology: Chenghao Zhao; Mingsheng Huang, Mingan Li. Project administration: Mingsheng Huang, Mingan Li. Resources: Mingsheng Huang, Mingan Li. Software: Chenghao Zhao, Huzheng Yan, Zhanwang **ang. Supervision: Mingsheng Huang, Mingan Li, Chenghao Zhao. Writing – original draft: Chenghao Zhao, Huzheng Yan, Haofan Wang. Writing – review & editing: Mingsheng Huang, Mingan Li.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University and complied with the Declaration of Helsinki 1975.
Consent to participate
Informed consent was obtained from legal guardians.
Consent to publish
Informed consent was obtained from all individual participants included in the study.
Competing interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhao, C., Yan, H., **ang, Z. et al. Idarubicin versus epirubicin in drug-eluting beads-transarterial chemoembolization for treating hepatocellular carcinoma: A real-world retrospective study. Invest New Drugs 41, 617–626 (2023). https://doi.org/10.1007/s10637-023-01377-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-023-01377-0